CRISPR (CRSP) to Focus on Next-Generation CAR T Pipeline
https://www.zacks.com/stock/news/2193794/crispr-crsp-to-focus-on-next-generation-car-t-pipeline?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2193794
Dec 05, 2023 - Based on early data from ongoing clinical studies, CRISPR (CRSP) has decided to focus on the development of its next-generation CAR T pipeline and discontinue its first-generation CAR T candidates.
0
BLUE, CRSP & VRTX Down Despite FDA Nod to SCD Therapies
https://www.zacks.com/stock/news/2196355/blue-crsp-vrtx-down-despite-fda-nod-to-scd-therapies?cid=CS-ZC-FT-analyst_blog|industry_focus-2196355
Dec 11, 2023 - The FDA approves two one-time gene therapies for treating sickle cell disease. One of them utilizes the Nobel prize-winning CRISPR/Cas9 gene-editing technology.
0
Biotech Stock Roundup: BLUE, CRSP & VRTX Get Gene Therapy Nod, ACAD Up on Patent News
https://www.zacks.com/stock/news/2198026/biotech-stock-roundup-blue-crsp-vrtx-get-gene-therapy-nod-acad-up-on-patent-news?cid=CS-ZC-FT-analyst_blog|stock_roundup-2198026
Dec 14, 2023 - bluebird (BLUE) and Vertex (VRTX) are in the spotlight this week on approval of therapies and pipeline news.
0
Biotech Stock Roundup: VRTX/CRSP Gene Therapy Label Expansion, ALLK Falls on Update
https://www.zacks.com/stock/news/2212227/biotech-stock-roundup-vrtx-crsp-gene-therapy-label-expansion-allk-falls-on-update?cid=CS-ZC-FT-analyst_blog|stock_roundup-2212227
Jan 18, 2024 - Vertex (VRTX), CRSP and Allakos are in the spotlight on regulatory and pipeline updates.
0